Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Rekha Badiger"'
Autor:
Rekha Badiger, Jane A Mitchell, Hime Gashaw, Neil A Galloway-Phillipps, Stefan Foser, Fernando Tatsch, Thomas Singer, Trevor T Hansel, Tobias Manigold
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e46779 (2012)
Alfa-interferons (IFNα2a, IFNα2b, 40KDa-PEGIFNα2a and 12KDa-PEGIFNα2b) are effective treatments for chronic hepatitis C infection. However, their usage has been associated with a variety of adverse events, including interstitial pneumonitis and p
Externí odkaz:
https://doaj.org/article/8b3d9158413b4a5190c0cfc5b2c0d180
Autor:
Gábor Földes, Alexander Liu, Rekha Badiger, Mark Paul-Clark, Laura Moreno, Zsuzsanna Lendvai, Jamie S Wright, Nadire N Ali, Sian E Harding, Jane A Mitchell
Publikováno v:
PLoS ONE, Vol 5, Iss 5, p e10501 (2010)
Treatment of human disease with human embryonic stem cell (hESC)-derived cells is now close to reality, but little is known of their responses to physiological and pathological insult. The ability of cells to respond via activation of Toll like recep
Externí odkaz:
https://doaj.org/article/630b5575a9964abdb08c95f3e4348367
Publikováno v:
Lung cancer.
The use of IPCs to manage malignant pleural effusion (MPE) is increasingly common. Prognosis in MPE is variable so scoring tools such as LENT and PROMISE may help select patients likely to benefit from IPC treatment. We wanted to determine which tool
Autor:
Morven Cunningham, Neil A. Galloway-Phillipps, Rekha Badiger, Graham R. Foster, Jane A. Mitchell, Peter M. George, William Alazawi
Publikováno v:
Pulmonary Circulation
Endothelin-1 is a potent vasoconstrictor and a therapeutic target in pulmonary arterial hypertension. Endothelial cells are the physiological source of endothelin-1 but in vitro data from our group shows that interferons (IFNα, IFNβ or IFNγ) induc
Autor:
Rekha Badiger, Michael R. Edwards, Peter M. George, Jane A. Mitchell, Stephen J. Wort, Dongmin Shao, Mark J. Paul-Clark
Publikováno v:
Biochemical and biophysical research communications. 426(4)
Pulmonary arterial hypertension (PAH) is a rare but fatal condition in which raised pulmonary vascular resistance leads to right heart failure and death. Endothelin-1 is a potent endogenous vasoconstrictor, which is considered to be central to many o
Publikováno v:
Pharmacologytherapeutics. 135(1)
Interferon (IFN) is widely recognised to be an integral part of the innate immune response to viral infection. Since its initial discovery in 1957 by Isaacs and Lindenmann, various IFN sub-types have been identified and there are now three distinct c
Publikováno v:
BMJ case reports. 2009
A 59-year-old builder presented to the accident and emergency department with a 4-week history of intermittent central chest pain. He was a lifelong non-smoker, had no asbestos or tuberculosis exposures, and had no cardiac risk factors. The …
Autor:
Alexander Liu, Rekha Badiger, Nadire N. Ali, Jamie S. Wright, Jane A. Mitchell, Gabor Foldes, Mark J. Paul-Clark, Zsuzsanna Lendvai, Laura Moreno, Sian E. Harding
Publikováno v:
PLoS ONE
PLoS ONE, Vol 5, Iss 5, p e10501 (2010)
PLoS ONE, Vol 5, Iss 5, p e10501 (2010)
Treatment of human disease with human embryonic stem cell (hESC)-derived cells is now close to reality, but little is known of their responses to physiological and pathological insult. The ability of cells to respond via activation of Toll like recep
Autor:
Ian M. Adcock, Misako Ito, Shaun K. Mc Master, Elen Jazrawi, Stephen J. Wort, Pai Chien Chou, Timothy W. Evans, Jane Mitchell, Rekha Badiger, Patricia M. De Souza, K. Ito, Liao Pinhu
Publikováno v:
The Journal of biological chemistry. 284(36)
Endothelin-1 (ET-1) is a potent vasoconstrictor and co-mitogen for vascular smooth muscle and is implicated in pulmonary vascular remodeling and the development of pulmonary arterial hypertension. Vascular smooth muscle is an important source of ET-1
Autor:
Neil A. Galloway-Phillipps, Thomas Singer, Jane A. Mitchell, Stefan Foser, Tobias Manigold, Fernando Tatsch, Rekha Badiger, Trevor T. Hansel, Hime Gashaw
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e46779 (2012)
PLoS ONE
PLoS ONE
Background Alfa-interferons (IFNα2a, IFNα2b, 40KDa-PEGIFNα2a and 12KDa-PEGIFNα2b) are effective treatments for chronic hepatitis C infection. However, their usage has been associated with a variety of adverse events, including interstitial pneumo